GCV Rising Star Paulo Braga, who leads Eurofarma’s corporate venturing fund, has spoken to Global Corporate Venturing about the unit's focus.
Brazil-based pharmaceutical firm Eurofarma’s corporate venture capital (CVC) arm seeks to identify digital technologies that can disrupt the healthcare ecosystem, Paulo Braga, head of the unit, told Global Corporate Venturing.
The vehicle was formed last month and has the capacity to invest up to R$45m ($11.7m) in early-stage healthcare technology developers.
“We do not focus solely on healthcare itself because we are looking for startups with solutions to transform any part of the value chain,” Braga said.
Areas that…
